Display options
Cite
Koop A, Sellami N, Adam-Klages S, et al. Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun Signal. 2013;11(1):41doi: 10.1186/1478-811X-11-41.
Koop, A., Sellami, N., Adam-Klages, S., Lettau, M., Kabelitz, D., Janssen, O., & Heidebrecht, H. J. (2013). Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell communication and signaling : CCS, 11(1), 41. https://doi.org/10.1186/1478-811X-11-41
Koop, Anja, et al. "Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration." Cell communication and signaling : CCS vol. 11,1 (2013): 41. doi: https://doi.org/10.1186/1478-811X-11-41
Koop A, Sellami N, Adam-Klages S, Lettau M, Kabelitz D, Janssen O, Heidebrecht HJ. Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun Signal. 2013 Jun 10;11(1):41. doi: 10.1186/1478-811X-11-41. PMID: 23758873; PMCID: PMC3689639.
Copy Download .nbib Format: NLM
Share it on

Cell Commun Signal. 2013 Jun 10;11(1):41. doi: 10.1186/1478-811X-11-41.

Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration.

Cell communication and signaling : CCS

Anja Koop, Nadia Sellami, Sabine Adam-Klages, Marcus Lettau, Dieter Kabelitz, Ottmar Janssen, Hans-Jürgen Heidebrecht

Affiliations

  1. Institute for Immunology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str, 3, Bldg 17, Kiel, 24105, Germany. [email protected].

PMID: 23758873 PMCID: PMC3689639 DOI: 10.1186/1478-811X-11-41

Abstract

BACKGROUND: Due to their restricted expression in male germ cells and certain tumors, cancer/testis (CT) antigens are regarded as promising targets for tumor therapy. CT45 is a recently identified nuclear CT antigen that was associated with a severe disease score in Hodgkin's lymphoma and poor prognosis in multiple myeloma. As for many CT antigens, the biological function of CT45 in developing germ cells and in tumor cells is largely unknown.

METHODS: CT45 expression was down-regulated in CT45-positive Hodgkin's lymphoma (L428), fibrosarcoma (HT1080) and myeloma (U266B1) cells using RNA interference. An efficient CT45 knock-down was confirmed by immunofluorescence staining and/or Western blotting. These cellular systems allowed us to analyze the impact of CT45 down-regulation on proliferation, cell cycle progression, morphology, adhesion, migration and invasive capacity of tumor cells.

RESULTS: Reduced levels of CT45 did not coincide with changes in cell cycle progression or proliferation. However, we observed alterations in cell adherence, morphology and migration/invasion after CT45 down-regulation. Significant changes in the distribution of cytoskeleton-associated proteins were detected by confocal imaging. Changes in cell adherence were recorded in real-time using the xCelligence system with control and siRNA-treated cells. Altered migratory and invasive capacity of CT45 siRNA-treated cells were visualized in 3D migration and invasion assays. Moreover, we found that CT45 down-regulation altered the level of the heterogeneous nuclear ribonucleoprotein syncrip (hnRNP-Q1) which is known to be involved in the control of focal adhesion formation and cell motility.

CONCLUSIONS: Providing first evidence of a cell biological function of CT45, we suggest that this cancer/testis antigen is involved in the modulation of cell morphology, cell adherence and cell motility. Enhanced motility and/or invasiveness of CT45-positive cells could contribute to the more severe disease progression that is correlated to CT45-positivity in several malignancies.

References

  1. Vaccine. 2007 Sep 27;25 Suppl 2:B61-71 - PubMed
  2. Nat Rev Cancer. 2005 Aug;5(8):615-25 - PubMed
  3. Curr Opin Immunol. 1997 Oct 1;9(5):681-3 - PubMed
  4. J Biol Chem. 2010 May 7;285(19):14475-85 - PubMed
  5. Mol Oncol. 2011 Apr;5(2):164-82 - PubMed
  6. Cancer Res. 2005 Mar 15;65(6):2207-15 - PubMed
  7. Mol Cell Biol. 2012 Jun;32(12):2224-38 - PubMed
  8. Biochem Biophys Res Commun. 2003 Jul 18;307(1):52-63 - PubMed
  9. Cancer Immun. 2008 Mar 12;8 Suppl 1:1 - PubMed
  10. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20422-7 - PubMed
  11. Int J Cancer. 2009 Jun 15;124(12):2893-8 - PubMed
  12. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702 - PubMed
  13. Exp Cell Res. 2006 Oct 15;312(17):3241-51 - PubMed
  14. Haematologica. 2010 May;95(5):785-93 - PubMed
  15. Mol Cancer Res. 2003 Feb;1(4):271-9 - PubMed
  16. Cell Adh Migr. 2012 Jul-Aug;6(4):374-84 - PubMed
  17. Blood. 2005 Jul 1;106(1):167-74 - PubMed
  18. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3093-8 - PubMed
  19. Am J Pathol. 1999 Mar;154(3):795-803 - PubMed
  20. J Microbiol Biotechnol. 2008 Mar;18(3):600-10 - PubMed
  21. EMBO J. 2001 Oct 1;20(19):5443-52 - PubMed
  22. EMBO J. 1999 Aug 2;18(15):4308-20 - PubMed
  23. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7940-5 - PubMed
  24. Cell. 1996 Feb 9;84(3):359-69 - PubMed
  25. Mol Biol Cell. 2012 Apr;23(8):1500-9 - PubMed
  26. J Invest Dermatol. 2007 Feb;127(2):267-75 - PubMed
  27. Nucleic Acids Res. 2009 Jan;37(Database issue):D816-9 - PubMed
  28. Clin Cancer Res. 2006 Aug 15;12(16):4804-11 - PubMed
  29. Cancer Immun. 2004 Jan 23;4:1 - PubMed
  30. Exp Hematol. 2009 Apr;37(4):446-9 - PubMed
  31. Mol Cell Biol. 1999 Nov;19(11):7327-35 - PubMed
  32. Cancer Cell. 2013 Jan 14;23(1):9-22 - PubMed

Publication Types